PRKAA2 and fatty liver disease: Pathophysiological studies have identified impaired AMPK signaling as a critical contributor to MASLD progression, with multiple preclinical investigations demonstrating that pharmacological AMPK activation effectively attenuates hepatic steatosis and inflammation in experimental models.